The hydrogel microsphere vaccine enhances in situ recruitment and amplification of tumour-resident CD103+ CD11b− cDC1s by rapidly releasing FLT3L, followed by the controlled release of CD40 agonist in the acidic TME, which further amplified activation and antigen-priming of cDC1s. Here, CD40 is linked to neoplasm.